Oxford University to Test Universal Flu Vaccine in World First

A nurse vaccinates a patient as part of the start of the seasonal influenza vaccination campaign in Nice, southeastern France, October 21, 2015.   REUTERS/Eric Gaillard
A nurse vaccinates a patient as part of the start of the seasonal influenza vaccination campaign in Nice, southeastern France, October 21, 2015. REUTERS/Eric Gaillard
TT

Oxford University to Test Universal Flu Vaccine in World First

A nurse vaccinates a patient as part of the start of the seasonal influenza vaccination campaign in Nice, southeastern France, October 21, 2015.   REUTERS/Eric Gaillard
A nurse vaccinates a patient as part of the start of the seasonal influenza vaccination campaign in Nice, southeastern France, October 21, 2015. REUTERS/Eric Gaillard

A seasonal flu vaccine that would be the first in the world to fight all types of the virus is to be tested in a two-year clinical trial involving more than 2,000 patients by researchers in Oxford.

The so-called universal vaccine was developed by Oxford University’s Jenner Institute and Vaccitech, a spin-out biotech company founded by Jenner scientists.

Current flu vaccines have to be changed each year to match strains of virus circulating at the time and they do not always protect people that well, especially older patients with weak immune systems.

The new vaccine works by using proteins found in the core of the virus rather than those on its surface. Surface proteins stick out like pins from the virus and change all the time, while those in the core are stable.

Significantly, the new vaccine works by stimulating the immune system to boost virus-killing T-cells, instead of antibodies. Previous research has shown such T-cells can help fight more than one type of flu virus.

Researchers hope the new vaccine will provide better and longer-lasting protection when used alongside the regular seasonal flu shot.

“We’re hoping it will last two to three years - maybe even four years - but we really don’t know until we do the trials,” Vaccitech Chief Executive Tom Evans told Reuters.

The new vaccine has already been tested for safety in earlier trials. Now it is advancing into mid-stage Phase IIb testing, which will see the recruitment of at least 500 British subjects this season. The remainder will be recruited during the 2018/9 flu season.

It is the first time a universal flu vaccine has progressed beyond Phase I clinical testing.

Assuming it is successful in Phase IIb, the new shot will still have to go into much bigger and expensive final-stage testing and Evans said the plan would be to bring in a partner at this stage of development.

“We would look for a better-capitalized company to take this into final Phase III tests,” he said.

Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL’s Seqirus, which includes the old Novartis flu vaccine business.



Madinah Red Crescent Saves Pilgrim's Life

Photo by SPA
Photo by SPA
TT

Madinah Red Crescent Saves Pilgrim's Life

Photo by SPA
Photo by SPA

Swift action by the Saudi Red Crescent ambulance teams in Madinah successfully revived a 50-year-old pilgrim who suffered a cardiac arrest at the Al-Miqat Mosque, SPA reported.
According to Dr. Ahmed bin Ali Al-Zahrani, director general of the Red Crescent's regional branch, their command center received a report about a pilgrim experiencing fainting and cardiac and respiratory arrest.

Ambulance crews immediately responded, and upon arrival, medical personnel initiated CPR (cardiopulmonary resuscitation) and applied an automatic blood pressure device. After stabilizing the patient and restoring his pulse, they transferred him to a hospital for further care.